Literature DB >> 16127085

Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Ana María Ríos1, Mónica Fonseca-Aten, Asunción Mejías, Susana Chávez-Bueno, Kathy Katz, Ana María Gómez, George H McCracken, Octavio Ramilo, R Doug Hardy.   

Abstract

We evaluated the efficacy of azithromycin therapy given as a single high dose or divided over 5 days for the treatment of mild experimental Mycoplasma pneumoniae pneumonia. Although both azithromycin regimens significantly reduced quantitative cultures, lung histopathology, and pulmonary cytokines and chemokines, there were no significant differences between the two regimens.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127085      PMCID： PMC1195405          DOI： 10.1128/AAC.49.9.3970-3973.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia.

Authors:  Robert D Hardy; Ana Maria Rios; Susana Chavez-Bueno; Hasan S Jafri; Jeanine Hatfield; Beverly B Rogers; George H McCracken; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response.

Authors:  K Tateda; Y Ishii; T Matsumoto; T Kobayashi; S Miyazaki; K Yamaguchi
Journal:  J Infect Chemother       Date:  2000-03       Impact factor: 2.211

4.  Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice.

Authors:  X X Bin; K Wolf; T Schaffner; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.

Authors:  R D Hardy; H S Jafri; K Olsen; M Wordemann; J Hatfield; B B Rogers; P Patel; L Duffy; G Cassell; G H McCracken; O Ramilo
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

6.  Structure-activity relationships for three macrolide antibiotics in Haemophilus influenzae.

Authors:  Susan Mabe; Jessica Eller; W Scott Champney
Journal:  Curr Microbiol       Date:  2004-10       Impact factor: 2.188

7.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 9.  Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.

Authors:  Bruce K Rubin; Markus O Henke
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

Review 10.  Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa.

Authors:  Daniel J Wozniak; Rebecca Keyser
Journal:  Chest       Date:  2004-02       Impact factor: 9.410
View more
  4 in total

1.  Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  C Tagliabue; C Techasaensiri; J P Torres; K Katz; C Meek; T R Kannan; J J Coalson; S Esposito; N Principi; R Leff; J B Baseman; R D Hardy
Journal:  J Antimicrob Chemother       Date:  2011-07-25       Impact factor: 5.790

2.  Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Authors:  C M Salvatore; C Techasaensiri; C Tagliabue; K Katz; N Leos; A M Gomez; G H McCracken; R D Hardy
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

3.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

4.  Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study.

Authors:  Forest W Arnold; Jose Bordon; Rafael Fernandez-Botran; Madhavi J Rane; Silvia M Uriarte; Robert Kelley; Timothy L Wiemken; Paula Peyrani; Julio A Ramirez
Journal:  Lung       Date:  2015-11-09       Impact factor: 2.584
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.